Mei Ri Jing Ji Xin Wen·2025-07-17 23:19Group 1 - Tigermed announced the sale of its stake in Lixin Pharmaceutical, holding a direct stake of 3.41% and an indirect stake of 4.58% through fund holdings, with the total transaction valued at approximately $34.11 million [1] - The sale reflects Tigermed's ability to achieve investment returns and demonstrates its professional post-investment management capabilities as a leading CRO [1] Group 2 - Yuan Da Pharmaceutical's innovative nasal spray product for dry eye treatment, OC-01, has received approval from the National Medical Products Administration and its first commercial prescriptions have been implemented [2] - The product's launch enhances Yuan Da's ophthalmology pipeline and signifies its strategic shift from a traditional pharmaceutical company to an innovative one, with future market performance being promising [2] Group 3 - China Pharmaceutical's general manager, Hu Huidong, has resigned due to work adjustments, which may lead to new development strategies if a new management team with rich industry experience is appointed [3] - The impact of this leadership change should be evaluated in conjunction with the company's fundamentals and subsequent announcements [3] Group 4 - Microchip Biotech expects a significant increase in net profit by 173% for the first half of 2025, with revenue projected at 407.29 million yuan, a 35% year-on-year increase [4] - The company is entering a harvest phase due to its independent R&D capabilities, validating its "small but beautiful" commercialization path, although it must continue to advance its pipeline and manage potential policy risks for sustained growth [4]